Goldfinch Bio Revenue and Competitors
Estimated Revenue & Valuation
- Goldfinch Bio's estimated annual revenue is currently $1.2M per year.
- Goldfinch Bio received $55.0M in venture funding in December 2016.
- Goldfinch Bio's estimated revenue per employee is $77,500
- Goldfinch Bio's total funding is $7.9M.
- Goldfinch Bio has 15 Employees.
- Goldfinch Bio grew their employee count by 25% last year.
Goldfinch Bio Competitors & AlternativesAdd Company
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Goldfinch Bio?
Goldfinch Bio is a biotechnology company that is singularly focused on discovering and developing precision therapies for kidney disease. Just as the goldfinch was a prominent figure of the Renaissance, Goldfinch Bio is leading a new age of therapeutic discovery to transform the treatment paradigm for patients with kidney disease. Goldfinch is integrating breakthroughs in kidney genetics and biology to identify new therapeutic targets and advance first-in-class drug candidates to treat patients with kidney disease. Our Product Engine will industrialize the integration of genetics and kidney biology and confer a differentiated ability to identify, validate, and pursue novel therapeutic targets to treat progressive kidney disease. At Goldfinch, were pioneering a new approach to discover and develop therapeutics that target the molecular basis of kidney disease. Were looking for teammates who relish the challenge, and are compelled to leave a positive mark on the lives of colleagues and patients alike.keywords:N/A
Number of Employees
Employee Growth %
Goldfinch Bio News
bio, a Boston-area biopharma recruitment and executive search firm that's worked with Rubius Therapeutics, Deciphera, Goldfinch Bio and others.
Goldfinch Bio, Inc. is a clinical stage biotechnology company focused on delivering disease-modifying precision medicines that bring hope...
Goldfinch Bio, Inc. is a clinical stage biotechnology company focused on delivering disease-modifying precision medicines that bring hope and...
Proceeds Support Advancement of Lead Product Candidates GFB-887 and GFB-024 Through Three Clinical Proof-of-Concept Readouts Oversubscribed Round Includes Public Healthcare Funds CAMBRIDGE, Mass.–(BUSINESS WIRE)–Goldfinch Bio, a clinical stage biotechnology company focused on discovering and d ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Goldfinch Bio Funding
|2016-12-15||$55.0M||A||Third Rock Ventures, LLC||Article|